It’s easy to find skepticism or hype when it comes to artificial intelligence, but it’s hard to get real facts and trends that matter for business leaders. That’s exactly what Daniel Faggella, founder of Emerj, an AI market research company, does each week on the AI in Business podcast.
This week’s guest is our very own Alexandre Le Bouthillier, Co-Founder of Imagia, where he discusses personalized medicine before and after artificial intelligence. He also brings to bear his perspectives on how personalized medicine might come to be, cutting through some of the buzzword hype surrounding the term.
“You want to remove and quantify the bias in the data, in the labeling technique, and in the model that you are creating and you have to think about the ecosystem. And it has to be allocentric. So – the hospital, the clinician, the Pharma and medical device companies; all have to have a buy-in into that.
This is why we think that by deploying our technology in multiple hospitals and as well enabling Pharma to use it on their own data or a mix of data, while preserving privacy and generating models that can be tested on live data, is very powerful.”
Don’t be on the wrong end of disruption – hear straight from AI’s best and brightest. Listen below:
Press Apr 21, 2022
Harnessing artificial intelligence to take the guesswork out of diagnosing cancer recurrence for millions of cancer survivors
Blog Apr 4, 2022
Personalized cancer treatment via targeted therapies is two-to-three times more effective than standard chemotherapy for patients with advan...
Press Feb 9, 2022
Imagia Cybernetics, an AI-healthcare company that accelerates oncology solutions generated from real world data, today announced its merger...
Please complete the form in order to direct your request to the appropriate department, and we will reach out as soon as possible.